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Background: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death in China. This study
investigated the effects of Annexin A7 (ANXA7) on the inhibition of HCC lymph node metastasis in a mouse model.
Methods: The stable knockup and knockdown of Annexin A7-expressing HCC cells using Annexin A7 cDNA and
shRNA vectors, respectively, were injected into a mouse footpad to establish primary and metastatic tumors in mice.
On the 14th, 21st, and 28th days after HCC cells inoculation, the mice were sacrificed for inspection of primary and
secondary tumors and immunohistochemistry of Annexin A7 expression.
Results: The lymph node metastasis rate of the FANXA7-control group was 77%, and the lymph node metastasis rate
of the FANXA7-down group was 100% (p < 0.05). In contrast, the lymph node metastasis rate of the PANXA7-up group
was 0% and that of the PANXA7-control group was 36% (p < 0.05). Furthermore, immunohistochemistry experiments
revealed that the subcellular localization of Annexin A7 protein in both primary and lymph node-metastasized
tumors was mainly in the cytosol. In addition, the expression of the 47 kDa and 51 kDa isoforms of Annexin A7
protein changed during tumor progression.
Conclusion: This study indicated that Annexin A7 expression was able to inhibit HCC lymph node metastasis,
whereas knockdown of Annexin A7 expression significantly induced HCC metastasis to local lymph nodes.
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Hepatocellular carcinoma (HCC), the most common
type of liver cancer, is a significant health problem in
the world due to its high incidence and mortality rate.
HCC accounts for more than 700,000 new cases and
over 500,000 deaths each year worldwide. HCC is het-
erogeneous and a highly aggressive malignancy; to date,
there are no effective means for a cure, due to high
invasion, early metastasis, and high tumor recurrence
after surgery or interventional treatment. Therefore,
early detection and prevention of HCC and the control
of HCC metastasis are urgently needed to improve
HCC prognosis. The risk factors for HCC include heavy
alcohol consumption, hepatitis B and C, aflatoxin, liver
cirrhosis, hemochromatosis, and type 2 diabetes; thus,
eradication of these risk factors could significantly
reduce HCC risk. Furthermore, HCC progression, like* Correspondence: jwtang_53@sina.cn
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reproduction in any medium, provided the ormetastasis, contributes to most human cancer deaths.
Mechanistically, metastasis involves multiple processes,
such as tumor cell proliferation, invasion, transportation,
arrest, adherence, extravasation, settling-down, and growth
in secondary sites [1]. Lymph node metastasis of a
tumor is considered as an important factor that is
involved in tumor progression.
However, the underlying molecular mechanisms involved
in lymph node metastasis of tumors remain undefined. To
date, a number of genes have been identified that modulate
lymphatic tumor metastasis when they are highly
expressed in certain tumor cells, such as Ezrin [2],
AF1QN [3], MMP-11 [4], or Annexin A7 [5,6]. Annexin
A7 is a member of the multifunctional calcium/
phospholipid-binding annexin family that functions as
a Ca2+-activated GTPase with membrane fusion properties.
A spliced cassette exon generally induces two isoforms
of Annexin A7 (47 kDa and 51 kDa). The 47 kDa isoform
is present in all tissues except for skeletal muscle, while
the 51 kDa isoform is exclusively present in the brain,This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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indicates that Annexin A7 is a membrane binding protein
with diverse properties, such as voltage-sensitive calcium
channel activity, ion selectivity, and membrane fusion
properties. However, the precise molecular action of
this protein is unclear, especially in HCC cell metastasis.
Our previous study demonstrated that Annexin A7
mRNA expression is 3.48-fold greater in Hca-F cells
than in Hca-P cells after cDNA microarray and gene chip
assays [5]; in addition, Annexin A7 protein expression
is three times higher in Hca-F cells than in Hca-P cells,
as shown by using two-dimensional differential in-gel
electrophoresis (2-D DIGE) minimal labeling analysis
[6], indicating that at the mRNA and protein levels,
Annexin A7 was more highly expressed in the Hca-F
cell line with a high potential for lymphatic metastasis
than in the Hca-P cell line with low potential for
lymphatic metastasis. These data suggest that Annexin
A7 may be a lymph node metastasis-associated gene
and may play a key role in HCC involved with lymph
node metastasis. Therefore, to gain more insight into
the potential mechanisms and associated genes that are
involved in HCC lymph node metastasis, we proposed
the current study by using two mouse hepatocarcinoma
ascites syngeneic cell lines, Hca-F (lymph node metastasis
rate >70%) and Hca-P (lymph node metastasis rate <30%)
[7-9] to assess the effects of Annexin A7 on the regulation
of HCC cell metastasis in an inbred Chinese 615 mouse
model of metastasis.Methods
Ethics statement
Inbred Chinese 615 mice (6–8 weeks old, SCXK (LIAO)
2008–0002) provided by the Experimental Animal Center
of Dalian Medical University. Mice were maintained under
standard conditions and treated according to the insti-
tutional guidelines for the use of laboratory animals.
All animal experiments were conducted in accordance
with protocols approved by the Experimental Animal
Ethical Committee of Dalian Medical University (Permit
Number: L2012012).Cell lines and culture
Both Hca-F and Hca-P cells were established and main-
tained in our laboratory [5,6]. Cells were grown in vitro
and then inoculated at 2 × 106 cells in a 0.2 ml cell
suspension into each inbred Chinese 615 mouse and
grown in the mouse abdominal cavity for 7 days. These
cells were drawn and injected again into another inbred
Chinese 615 mouse and grown for 5 days. Then, those
cells were routinely cultured in RPMI-1640 (Gibco,
CA, USA) supplemented with 10% fetal bovine serum
(PAA, CA, USA) at 37°C in a humidified incubator with5% CO2 and 95% air. For Annexin A7 gene transfection
subcell populations, they were maintained in the same
conditions except for cultivating in RPMI-1640 supple-
mented with 10% FBS and 400 μg/ml G418 (Calbiochem,
CA, USA).Expression vector construction and gene transfection
To knockdown Annexin A7 expression in Hca-F cells,
we constructed three shRNA plasmids (Annexin A25,
Annexin A59, and Annexin A507) using mouse Annexin
A7 cDNA (accession # NM_009674.3). The target se-
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TTTGCG-3′. The primer for M13F was 5′-GTTTTCC
CAGTCACGAC-3′. After annealing into double-stranded
DNA, these shRNA oligonucleotides were then inserted
into pSilencer™ 3.1-H1 neo plasmids (Shanghai ZJ Bio-
Tech, China) using the BamHI and HindIII sites and
transfected into Escherichia coli DH5α for amplification.
After sequence confirmation, these plasmids were then
used for stable gene transfection. To increase Annexin
A7 expression in Hca-P cells, the Annexin A7 gene
was amplified, and BamH 1 and EcoR I enzymes were
used. The pcDNA3.1-Annexin A7 expressing vectors
was constructed.
Hca-F and Hca-P cells with a density of 1 × 106 cells/
well were cultured in six-well plates with serum-free
RPMI-1640 medium. These plasmids and “empty” vector
were transfected into Hca-F cells using 15 μL of Lipofec-
tamine 2000 (Invitrogen, CA, USA) according to the
manufacturer’s instructions and cultivated in RPMI-1640
medium. After that, the cells were cultured in RPMI-
1640 medium containing G418 (400 μg/mL) to establish
a stable subcell population. After 16 days, approximately
85–95% of the cells were eliminated, and the remaining
cells were continuously cultured in RPMI-1640 medium
containing G418 (400 μg/mL) for our experiments. Hca-F
and Hca-P cells were each divided into three groups:
♦ Unmanipulated Hca-F cells were used as the control
(Hca-F).
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(FANXA7-control).
♦ shRNA-ANXA7 plasmids were transfected into
Hca-F cells (FANXA7-down).
♦ Unmanipulated Hca-P cells were used as the control
(Hca-P).
♦ Empty plasmids were transfected into Hca-P cells
(PANXA7-control).
♦ pcDNA3.1-ANXA7 plasmids were transfected into
Hca-P cells (PANXA7-up).
RNA isolation and reverse transcription polymerase chain
reaction (RT-PCR)
Total RNA was isolated from the cultured cells using
Trizol (Invitrogen, USA), according to the manufacturer’s
instructions. After RNA isolation, cDNA was prepared
from each sample by using 2 μg of total RNA for reverse
transcription in a mixture, consisting of 4 μL of 5×
RT-buffer, 2.5 μM oligo(dT) primers, 5 mM dNTPs, 20 U
RNasin, and reverse transcriptase (Promega, CA, USA).
The PCR mixture contained 4 μL of 10× buffer, 0.8 μL
of 10 mM dNTP, 3.2 μL of 25 mM MgCl2, 0.5 μL of
each primer, and 0.3 μL of 5 U Taq DNA gold Polymerase
(Takara, CA, Japan). The PCR conditions were as follows:
95°C for 5 min; 30 cycles of 94°C for 15 s, 57°C for 20 s,
and 72°C 60 s; and a final extension at 72°C for 10 min.
The Annexin A7 primers were 5′-TGTCTAACCGTTC
CAATGACC-3′ (upstream) and 5′-GGATTCATCCGTT
CCCAGTC-3′ (downstream).Protein extraction and western blot
Total cellular protein was extracted using a buffer contain-
ing lysate, DTT, PMSF, and cocktail (Roche, CA, China).
Next, protein samples were fractionated by using 12%
SDS-PAGE. Annexin A7 antibody (A4475, Sigma, USA)
was used at a dilution of 1:1500 for western blot, and
GAPDH antibody (Kangchen, CA, China) was used at a
dilution of 1:7500. The secondary antibody (Zhongshan
Golden Bridge, CA, China) was used at a dilution of
1:4000 for both Annexin A7 and GAPDH. Positive protein
bands were visualized by using electrochemiluminescence
reagents (Santa Cruz Biotechnologies, CA, USA) and
quantified by using densitometry (Bio-Rad, CA, USA).
Animal experiments
A total of 84 Inbred Chinese 615 mice were provided
by the experimental animal housing facility at Dalian
Medical University. The mouse model of HCC cell
lymphatic metastasis was established by injection of
HCC cells into the left footpad of inbred Chinese 615
mice (called “primary tumor”). The number of cells
injected into each mouse was 2 × 106/0.05 ml. On the
14th, 21st, and 28th days after tumor cell inoculation,the mice were sacrificed and examined. During these
periods of time, all of the inoculated tumor cells developed
xenografts in the footpad for Hca-F, FANXA7-control,
FANXA7-down, Hca-P, PANXA7-control, and PANXA7-up groups.
Some of the mice also developed metastatic tumors in
different regional lymph nodes, which were called “me-
tastasized lymph nodes”, including popliteal, inguinal,
and iliac artery lymph nodes. Lymph nodes volumes
(V) were calculated by the formula V = L ×W2 × 0.5. All
primary and secondary tumor xenografts were collected
for processing by hematoxylin and eosin (HE) staining.
In addition, protein samples from the primary tumor
were extracted for western blot analysis of Annexin A7
protein expression. Meanwhile, protein samples from
the primary tumor in the Hca-F cell group on the 14th,
21st, and 28th days were called “F14” group, “F21” group,
and “F28” group, respectively; protein samples from the
primary tumor in the FANXA7-down cell group on the
28th day were called the “FANXA7-down28” group; protein
samples from the primary tumor in the Hca-P cell
group on the 14th, 21st, and 28th days were called
“P14” group, “P21” group, and “P28” group, respectively;
protein samples from the primary tumor in the PANXA7-up
cell group on the 28th day were called the “PANXA7-up28”
group. The popliteal, iliac artery, and inguinal lymph
nodes were collected for HE staining and immunohis-
tochemistry to examine potential secondary tumors and
Annexin A7 expression under a microscope.Immunohistochemistry
Immunohistochemistry was used to detect Annexin A7
expression in the mouse xenografts. A mouse monoclonal
antibody against Annexin A7 was used at a dilution of
1:200. A rabbit anti-mouse secondary antibody (Santa
Cruz Biotechnology, CA, USA) was used at a 1:1000 di-
lution. Annexin A7 protein expression was quantified
based on staining intensity and uniformity of nuclear/
cytoplasmic staining. The percentage of staining was
scored as 1, ≤10%; 2, 11-50%; 3, 51-75%; and 4, >75%.
Staining intensity was scored as 0, no staining; 1, stra-
mineous color; 2, yellow color; and 3, brown. Next,
these scores were combined to give a final score for
each section as - to +++ (−, no signal; +, weak indeter-
minate signal; ++, moderate signal; +++, strong signal).
All sections were stained simultaneously, together with
the appropriate positive and negative controls.Statistical analysis
Statistical analysis was performed using the χ2-test
and standard one-way analysis of variance (ANOVA)
or one-way ANOVA for repeated measures. Immuno-
histochemical data were compared using a rank-sum test.
A p-value < 0.05 was considered statistically significant.
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Establishment of stable knockup and knockdown of
Annexin A7-expressing HCC cells
In this study, we established stable cells that expressed
knockdown of Annexin A7 in Hca-F cell lines. The
RT-PCR results showed that different constructs of
shRNA had different knockdown efficiencies of Annexin
A7 expression. While, the transfection efficiency of
pSilencer-Annexin A25 shRNA was better than those
of Annexin A59 and Annexin A507 in silencing
Annexin A7 gene expression in Hca-F cells 24 h after
transfection (Figure 1A). The Δct values of Hca-F,
FANXA7-control, and FANXA7-down cells were 2.02, 3.06,
and 4.88, respectively. Western blot results indicated
that the expression of Annexin A7 in FANXA7-down was
significantly lower than FANXA7-control, but Annexin A7
expression in Hca-F showed no difference compared to
FANXA7-control (Figure 1C). These data showed that Hca-
F cells had downregulated expression of Annexin A7,
not only at the gene level but also at the protein level.
The RT-PCR data showed that the Δct value of
Annexin A7 gene expression in Hca-P cells was 0.54,
and in PANXA7-up cells it was 0.24 (Figure 1B). Western
blot analysis showed that Annexin A7 expression in
PANXA7-up cells was greater than in PANXA7-control, but
Annexin A7 expression in Hca-P showed no difference
compared to PANXA7-control (Figure 1D). These data
illustrated that the pcDNA3.1-Annexin A7 expression
vector was successfully constructed and stably expressed
in Hca-P cells, indicating that Hca-P cells had upregulated
expression of Annexin A7 both at the gene and protein
levels after gene transfection.
Effects of Annexin A7 on the regulation of HCC cell lymph
node metastasis in a mouse model
The above results evidently indicate that Annexin A7 was
successfully downregulated in Hca-F cells and upregulatedFigure 1 Expression of Annexin A7 mRNA and protein. (A) RT-PCR ana
constructs (Annexin A25, Annexin A59, and Annexin A507). pSilencer-Anne
pSilencer-Annexin A59 shRNA. (B) RT-PCR analysis of Annexin A7 mRNA expre
Hca-F, FANXA7-control, and FANXA7-down cells. (D) Western blot analysis of Annexinin Hca-P cells. After the two stable cell lines were
established, they were injected into the footpads of
inbred Chinese 615 mice to ensure that all the mice
developed a “primary tumor”. The metastatic tumor
xenografts developed in the lymph nodes (Figure 2A).
The results showed that the lymph node metastasis rate
of the FANXA7-control group was 77%, and that of the
FANXA7-down group was 100% (p < 0.05, Table 1), indicating
that after downregulation of the Annexin A7 gene in
Hca-F cells with high lymphatic metastasis potential, the
lymph node metastasis rate was increased significantly
in vivo. In contrast, the lymph node metastasis rate of the
PANXA7-up group was 0% and that of the PANXA7-control
group was 36% (p < 0.05, Table 1), demonstrating that
Annexin A7 protein expression significantly reduced
lymph node metastasis upon upregulation of the Annexin
A7 gene in Hca-P cells.
The metastasized lymph nodes included the popliteal,
inguinal, and iliac artery lymph nodes. The data indi-
cated that the volumes of the popliteal and inguinal
lymph nodes were significantly larger than the iliac
artery lymph nodes (p < 0.05), and the volumes of the
popliteal lymph nodes were significantly larger than the
inguinal lymph nodes (p < 0.05) (Figure 2B). The metas-
tasized lymph nodes stained with HE showed that no
obvious morphological differences were noted in metas-
tasized lymph nodes of the FANXA7-control, FANXA7-down,
and PANXA7-control groups (Figure 2C).
Expression and subcellular localizations of Annexin A7
protein in mouse xenografts
Next, we analyzed the expression and subcellular local-
ization of Annexin A7 in mouse primary tumor tissue
and metastatic lymph nodes using immunohistochemistry.
We found that the subcellular localization of Annexin A7
protein in primary and lymph node-metastasized tumors
was mainly in the cytosol, and some of the Annexin A7lysis of Annexin A7 gene silencing in Hca-F cells using three shRNA
xin A25 shRNA was more potent than pSilencer-Annexin A507 and
ssion in Hca-P cells. (C) Western blot analysis of Annexin A7 expression in
A7 expression in Hca-P, PANXA7-control, and PANXA7-up cells.
Figure 2 Metastatic lymph nodes. (A) The white arrow indicates the metastatic inguinal lymph node, and the black arrow indicates a
metastatic popliteal lymph node. (B) The volumes of metastatic popliteal, inguinal, and iliac artery lymph nodes. (C) The metastatic lymph nodes
of FANXA7-control, FANXA7-down, and PANXA7-control were fixed in 10% neutral-buffered formalin, paraffin-embedded, and cut into 4-μm sections for HE
staining (400×).
Table 1 Lymph node metastasis rates in hepatocarcinoma











FANXA7-control 13 10 77 0.018
FANXA7-down 34 34 100
PANXA7-control 11 4 36 0.005
PANXA7-up 26 0 0
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membrane (Figure 3). The expression intensity of Annexin
A7 protein between high and low lymph node-
metastasized tumors was also different: there was
lower Annexin A7 expression in primary FANXA7-down
tumor cells than in FANXA7-control tumors (p < 0.05). In
addition, Annexin A7 expression was greater in primary
tumors of PANXA7-up cells than in those of PANXA7-control
cells (p < 0.05). Furthermore, Annexin A7 expression
was greater in lymph node-metastasized tumors derived
from FANXA7-down cells than from FANXA7-control cells
(p < 0.05). Likewise, Annexin A7 expression was greater
in FANXA7-control primary tumor cells than in lymph
node-metastasized tumors (p < 0.05; Table 2).
Figure 3 Immunohistochemistry analysis of Annexin A7 expression in primary tumor and metastatic lymph node tissues. The subcellular
localization of Annexin A7 protein in primary tumor cells was mainly in the cytosol and partially in the cell membrane, while Annexin A7 expression in
lymph node metastatic tumors was only localized in the cytosol. All magnifications are × 400.
Jin et al. BMC Cancer 2013, 13:522 Page 6 of 9
http://www.biomedcentral.com/1471-2407/13/522Expression of Annexin A7 levels in high- and low-lymph
node-metastasized primary tumors
We investigated the time course of primary tumor forma-
tion in mice and found that on the 14th, 21st, and 28th
days after tumor cell inoculation, both the 47 kDa and
51 kDa isoforms of Annexin A7 protein were detected
in the “primary tumor” with different expression levels.
Expression of the 47 kDa isoform in the FANXA7-down28
group was less than that in the F28 group. The expression
of the 51 kDa isoform in the PANXA7-up28 group was
greater than that in the P28 group (Figure 4A). In Hca-F
cells with a high lymphatic metastasis potential, expression
of the 47 kDa and 51 kDa isoforms was consistent with
the total protein that was found on the 14th day, which
was the highest point, and on the 21st day, which was
the lowest level; while on the 28th day, the protein
expression increased (Figure 4A, 4B). Whereas in Hca-
P cells with a low lymphatic metastasis potential, theTable 2 Annexin A7 protein expression in primary and lymph
Tissue N Annexi
- +
FANXA7-control primary tumor 13 0 2
lymph node metastasized tumor 16 10 1
FANXA7-down primary tumor 34 8 22
lymph node metastasized tumor 66 15 8
PANXA7-control primary tumor 11 5 5
Lymph node metastasized tumor 4 0 0
PANXA7-up primary tumor 26 1 5
P-value 1 shows the difference among different groups. *The expression of Annexin
expression of Annexin A7 in primary tumors of PANXA7-up cells vs. that of PANXA7-cont
FANXA7-down cells vs. that of FANXA7-control cells.
P-value 2 shows the difference within the group. ◆The expression of Annexin A7 in
tumors. ■The expression of Annexin A7 in lymph node metastasized tumors of FANX
lymph node metastasized tumors of PANXA7-control cells vs. that of primary tumors.expression level of the 47 kDa isoform of Annexin A7
was consistent with the total protein, which decreased
over time, while that of the 51 kDa isoform increased
over time (Figure 4A, 4C).
Discussion
In this study, we investigated the effects of Annexin A7
on HCC and lymphatic metastasis in a mouse model of
lymph node metastasis by using the two mice hepatocar-
cinoma ascites syngeneic cell lines Hca-F and Hca-P
with high and low lymphatic metastasis potential, respect-
ively. The data showed that the lymph node metastasis
rate was decreased from 36% to 0% after upregulation of
Annexin A7 in Hca-P cells, but it increased from 77% to
100% after downregulation of Annexin A7 expression in
Hca-F cells. Thus, the in vivo data implied that Annexin
A7 may play an important role in HCC lymphatic me-
tastasis and play a tumor suppressor function in HCC.node metastasized tumors
n A7 expression p-value 1 p-value 2
++ +++




1 0 0.000Δ 0.001●
1 3
7 13
A7 in primary tumors of FANXA7-down cells vs. that of FANXA7-control cells. Δ The
rol cells. # The expression of Annexin A7 in lymph node metastasized tumors of
primary tumors of FANXA7-control cells vs. that of lymph node metastasized
A7-down cells vs. that of primary tumors.
●The expression of Annexin A7 in
Figure 4 Western blot analysis of Annexin A7 expression at different phases of tumor formation. (A) Expression of Annexin A7 proteins
(47 kDa and 51 kDa) at 14th, 21st, and 28th days after inoculation of Hca-F cells. (B) Quantification of Annexin A7 (47 kDa and 51 kDa isoforms)
expression at 14th, 21st, and 28th days after Hca-F cell inoculation. (C) Quantification of Annexin A7 (47 kDa and 51 kDa isoforms) expression at
14th, 21st, and 28th days after Hca-P cell inoculation.
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sion is lost in metastatic and local recurrent hormone-
refractory prostate cancer compared to primary tumors
[10]. Srivastava et al. reported the knockout of the
Annexin A7 gene in mice to investigate the involvement
of Annexin A7 in Ca2+ signaling in secreting pancreatic
β cells and its function in the control of cancer develop-
ment [11,12]. Annexin A7 has been shown to be a tumor
suppressor in hormone-relevant prostate and breast
cancers [10-15]. In prostate cancer, Annexin A7 as a tumor
suppressor could be through inhibition of pathologic
androgen signaling and dysfunctional retinoblastoma 1,
PTEN, and p53 activity. Annexin A7 could also be as-
sociated with its mediation of exocytosis and secretion
in prostate cells and possibly in other cancers [14]. In
addition, haplo-insufficiency of Annexin A7 expression
appears to drive disease progression to cancer because
the genomic instability could lead to a discrete signaling
pathway to reduce expression of the other tumor sup-
pressor genes, DNA-repair genes, or apoptosis-related
genes [12]. Some work regarding Annexin A7 from our
laboratory clearly showed that the Annexin A7 gene is
associated with lymph node metastasis and progression
of HCC [5-7,16-19]. However, the tumor suppressor
mechanisms of Annexin A7 in HCC have not yet been
elucidated. Future studies will investigate Annexin A7
expression ex vivo before Annexin A7 expression is
used to control HCC progression in the clinic.Immunohistochemistry experiments showed that the
subcellular localization of Annexin A7 protein in both the
primary and lymph node-metastasized tumors was mainly
in the cytosol, with some in the nuclei and cell membrane;
while the level of Annexin A7 expression in the tumors
was associated with their metastasis potential. Our current
study demonstrated that the subcellular localization of
Annexin A7 protein may be involved with lymph node
metastasis of HCC. Meanwhile, Asma et al. found that
Annexin A7 protein can be localized in the cytosol, on the
cell membrane, or on the cytoskeleton [17]. Furthermore,
Rick et al. detected both of the Annexin A7 isoforms
(47 kDa and 51 kDa) in a diabetes-related animal model.
Diabetic wild-type animals showed reduced levels of
the 47 kDa protein isoform. During brain development,
Annexin A7 expression changes from the cytoplasm to
the nuclei, and the subcellular distribution of Annexin
A7 protein depends on the cell type in the adult central
nervous system [20]. In this study, we found that
Annexin A7 expression was different in metastasized
lymph nodes and primeval tumor cells derived from
Hca-P and Hca-F cells. This disparity illustrates that the
Annexin A7 gene plays an important role in high and low
lymph node metastasis. This result was supported by a
study that disclosed that the loss of Annexin A7 is an
important factor in distant metastasis of gastric cancer
[21]. In addition, altered expression of Annexin A7 could
affect the tumor stage and survival in hormone-refractory
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Annexin A7 can regulate cellular exocytosis [25,26],
and the latter event was associated with tumorigenesis
[27]. Annexin A7 can also modulate neoangiogenesis and
tumor invasiveness through its involvement in VEGFR1
signaling [28]. Ras proteins control at least three crucial
signaling networks, including anchorage independence,
survival, and proliferation protein dysregulated pathways,
such as Annexin A7 [29]. Annexin A7 can translocate
from the cytoplasm to the cellular membrane in cul-
tured cells after damage, apoptosis, and treatment with
Ca2+-ionophore [30]. The 47 kDa isoform of Annexin
A7 is expressed in astrocyte-derived C6 rat glioblastoma
cells, which is in contrast to human brain tissues [31].
Both isoforms appear in red blood cells, heart muscle, and
the brain [31-35]; different isoforms with a tissue-specific
distribution may indicate different functions of Annexin
A7 [34]. Our experiments showed that both the 47 kDa
and 51 kDa isoforms of Annexin A7 occurred in hepato-
carcinoma tissues. In Hca-F cells with a high metastasis
potential, the 47 kDa isoform was abundant; whereas
in Hca-P cells with a low metastasis potential, the
51 kDa isoform was dominant. In addition, the expression
of the 47 kDa and 51 kDa isoforms varied over time;
thus, these data suggest that both isoforms play differ-
ent roles in HCC progression. Afterwards, we detected
Annexin A7 expression in mouse xenografts from primary
and secondary tumors and found that the expression
levels of Annexin A7 in tumors were reversely associated
with their metastasis potential, indicating that Annexin
A7 does play a role in suppression of tumor metastasis
in vivo. These data demonstrate that Annexin A7 functions
as a tumor suppressor gene in hepatocarcinoma and
could be further evaluated as a novel therapeutic target
for hepatocarcinoma.
In summary, our current data demonstrate that the
dysregulation of Annexin A7 is an important factor
associated with lymph node metastasis of HCC. Further
mechanistic studies will provide more insight into
Annexin A7 tumor suppressor function for potential
diagnostic and therapeutic uses.
Conclusion
In summary, our study indicated that Annexin A7
expression was able to inhibit HCC lymph node me-
tastasis, indicating that the Annexin A7 gene might
play an important role in the process of tumor lymph
node metastases.
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